With BioNTech and Moderna advancing personalised cancer vaccine trials, CEPI backing rapid response platforms, and groundbreaking innovations in saRNA, circRNA, and gene editing, the mRNA field entered a new era of opportunity in 2025.

As the industry continued its shift from pandemic response to long-term therapeutic promise, drug developers faced growing pressure to reduce production timelines, de-risk regulatory submissions, and scale robust, reproducible, and compliant mRNA platforms.

The 4th mRNA Process Development & CMC Summit successfully returned as the world’s only flagship forum dedicated to overcoming bottlenecks across the mRNA value chain from designer enzymes and IVT to purification and room-temperature stabilization empowering mRNA therapeutic and vaccine developers to advance safer, more effective mRNA drugs.

Featuring in-depth sessions on DNA material sourcing, dsRNA control, in-process analytics, next-gen formulations, digital twins, lyophilization, saRNA, and regulatory readiness, the summit brought together the entire mRNA manufacturing ecosystem to drive forward real-world implementation and clinical impact.

Whether scaling up, building analytical and CMC control strategies, or aligning with evolving FDA expectations, attendees gained the technical insights, regulatory clarity, and peer-driven strategies needed to accelerate mRNA drug development with greater confidence and precision.

The event convened global mRNA leaders from Sanofi, GSK, Moderna, AstraZeneca, CSL, BioNTech, CEPI, US Pharmacopeia, CureVac, and Editas Medicines, along with 125+ global experts to walk away with the ultimate mRNA manufacturing roadmap.